LifeStance Health Group, Inc. (LFST)
SobrevaloradaFundamental
58
Precio
$11.98
Capitalización Bursátil
$4.57B
Parte 1 · Cuánto vale la empresa
Resumen
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 19 de septiembre de 2026 with claude-haiku-4-5 — shared with all users
Its behavioral health division has been adding outpatient mental-health locations across the US, competing market by market with LifeStance for the same commercially insured patients.
A privately held multi-state outpatient psychiatry and therapy group with 80+ clinics plus telehealth, competing for the same insured US patients and the same clinicians as LifeStance's hybrid clinic model.
A private national psychiatry practice in network with more than 60 US insurers, competing directly for the insurance-covered psychiatry and medication-management visits that are LifeStance's core revenue.
Offers insurance-covered virtual therapy and psychiatry to US consumers and employers, competing for the same outpatient mental-health visits that LifeStance delivers by telehealth.
A private platform that puts independent US therapists and psychiatrists in network with commercial payors, competing with LifeStance both for patients looking for an in-network clinician and for the clinicians themselves.
Through BetterHelp it is the largest virtual therapy brand in the US and is moving from cash-pay to insurance coverage, meeting LifeStance on the same outpatient therapy demand.
Balance y Liquidez
Ingresos
$1.58B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$51M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$110M
Patrimonio Neto Total
$1.52B
Pasivo Total
$683M
Ratio de Liquidez
1.38
Cobertura de Intereses
7.75
Deuda/EBITDA
7.21
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$8.76
Precio Actual
$11.98
Margen de Seguridad
-36.8%
Rango de Valor Justo
$5.69 - $11.82
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
92.54
ROE
0.6%
Ratio P/B
3.11
P/FCF
26.43
Margen Bruto
-
ROIC
3.3%
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
3.3%
WACC
11.1%
ROIC − WACC
-7.8 pp
El ROIC está por debajo del coste del capital: la empresa destruye valor por cada dólar invertido.
Criterios de Análisis Fundamental
Superado (13)
- EPS shows upward trend
- P/FCF 26.43
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Return on Tangible Assets
- Revenue Growth 5Y 30.4%
- Analyst Consensus 78% Buy
- Earnings Surprise avg 621.9%
- Earnings Quality (OCF/NI) 4.31
- Net Margin Trend 3.2% vs -1.2%
- Piotroski F-Score 7/9
Fallido (11)
- Price CAGR 4.88%
- ROIC 3.2%
- P/B Ratio 3.11
- Operating Margin 4.9%
- CapEx intensity
- Debt/EBITDA
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.4%
- Share Dilution 26.2%
No disponible (3)
- Gross Margin NaN%
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Solidez financiera fuerte
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Emitiendo nuevas acciones, diluyendo la participación
Participaciones institucionales
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Kenneth Alan Burdick J.D. | Executive Chairman | 66 |
| Mr. David Patrick Bourdon | CEO & Director | 56 |
| Mr. Ryan Bruce McGroarty | CFO & Treasurer | 52 |
| Mr. Vukasin Paunovich | Chief Technology Officer | 53 |
| Mr. Ryan Pardo J.D. | Chief Legal Officer & Secretary | 48 |
| Ms. Ann Varanakis | Chief People Officer | 47 |
| Ms. Lisa Keise Miller | Chief Operating Officer & Principal Operating Officer | 51 |
| Ms. Monica Prokocki | Vice President of Investor Relations | - |
| Brooke Matthews | Director of Public Relations | - |
| Mr. Richard Hall | Chief Shared Services Officer | - |
Riesgo de Auditoría
10
Riesgo del Consejo
10
Riesgo de Compensación
7
Riesgo de Derechos del Accionista
8
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Documentos
- Ver documento
Informe anual (10-K)
Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.
Presentado el 2026-02-25
- Ver documento
Informe trimestral (10-Q)
Una actualización del desempeño financiero de los últimos tres meses.
Presentado el 2026-08-06
- Ver documento
Informe de hecho relevante (8-K)
Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.
Presentado el 2026-09-11
via SEC EDGAR
Historial de Resultados
via SEC EDGAR
Latest News
Recent headlines for LFST, sourced from Markets Gazette.
- 2/25/2026NEUTRALLifeStance (LFST) Q4 2025 Earnings Call Transcript
The transcript for LifeStance Health Group, Inc.'s (LFST) Q4 2025 earnings call is now available. Investors and analysts have been keenly awaiting this document to gain in-depth insights into the company's financial performance for the period. While the specific content has not been disclosed in this announcement, the release of the transcript is a crucial event for market transparency. Market participants will now focus on analyzing management's statements, future projections, and responses to analyst questions to assess LifeStance's operational health and growth prospects. The market's reaction will hinge on the key metrics presented and the guidance provided.
via Markets Gazette